Transjugular Intrahepatic Portosystemic Shunt Versus Conventional Treatment for Improvement in Portal Hypertension
International Journal of Current Pharmaceutical Review and Research · 28.02.2026 · 18 (02)
DOI: 10.25258/ijcpr.18.2.295 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 28.02.2026. Verfasst von Pankaj Goyal und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
The present paper evaluates transjugular intrahepatic portosystemic shunt (TIPS) in comparison with conventional treatment strategies for improvement in portal hypertension, with particular attention to hemodynamic efficacy, control of variceal bleeding, management of refractory ascites, prevention of recurrent decompensation, and treatment-related adverse events. Materials and Methods: This paper is a narrative, evidence-based comparative review based on current practice guidance, consensus recommendations, and meta-analytic data concerning TIPS and conventional treatment for portal hypertension. Data were synthesized under clinically relevant themes: pathophysiological basis, indications, patient selection, procedural endpoints, conventional comparators, outcomes in variceal bleeding and refractory ascites, post-procedural complications, and practical interpretation for present-day management.
Result
The comparative evidence shows that TIPS provides stronger portal decompression than conventional therapy because it directly lowers portal pressure gradient, whereas conventional therapy generally modifies bleeding risk or fluid accumulation indirectly. In variceal bleeding, TIPS reduces recurrent variceal bleeding more effectively than endoscopic therapy, and early TIPS in selected high-risk patients improves one-year mortality while markedly lowering rebleeding risk. In refractory ascites, TIPS is superior to serial paracentesis for ascites control and reduces repeated paracentesis requirements, but this benefit is offset by a greater risk of hepatic encephalopathy and by inconsistent survival advantage across older meta-analyses.
Conclusion
TIPS is not simply an alternative to conventional treatment; it is a mechanistically distinct portal decompressive therapy with superior efficacy for selected complications of portal hypertension. Conventional treatment remains foundational for initial stabilization, first-line bleeding management, and broad clinical applicability, but TIPS is superior in reducing recurrent variceal bleeding and in controlling refractory ascites in appropriately selected patients.
Zitieren
APA
Goyal, P., Khan, A., & Ahirwar, L. (2026). Transjugular Intrahepatic Portosystemic Shunt Versus Conventional Treatment for Improvement in Portal Hypertension. International Journal of Current Pharmaceutical Review and Research, 18(02). https://doi.org/10.25258/ijcpr.18.2.295
Vancouver
Goyal P, Khan A, Ahirwar L. Transjugular Intrahepatic Portosystemic Shunt Versus Conventional Treatment for Improvement in Portal Hypertension. International Journal of Current Pharmaceutical Review and Research. 2026;18(02). doi:10.25258/ijcpr.18.2.295
BibTeX
@article{Goyal2026,
author = {Goyal, Pankaj and Khan, Adnan and Ahirwar, Laxman},
title = {Transjugular Intrahepatic Portosystemic Shunt Versus Conventional Treatment for Improvement in Portal Hypertension},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {02},
doi = {10.25258/ijcpr.18.2.295}
}
EUVIMED